Robuta

https://bridgebio.com/ Home | BridgeBio BridgeBio is a biotechnology company designing transformative medicines for patients with genetic diseases and cancers with clear genetic drivers. bridgebio https://www.fiercebiotech.com/biotech/bridgebio-spins-out-ultra-rare-genetic-disease-company-after-acquiring-enzyme-from-alexion BridgeBio spins out ultrarare genetic disease company after acquiring enzyme from Alexion | Fierce... Jun 11, 2018 - Through an agreement with Alexion Pharmaceuticals, BridgeBio Pharma acquired a synthetic enzyme replacement therapy for an ultrarare, fatal genetic disease... https://www.macrotrends.net/stocks/charts/BBIO/bridgebio-pharma/pe-ratio BridgeBio Pharma PE Ratio 2018-2026 | BBIO | MacroTrends pe ratiobridgebiopharmamacrotrends https://builtin.com/job/neuromuscular-account-manager-new-orleans-la/8992833 Neuromuscular Account Manager - New Orleans, LA - BridgeBio | Built In BridgeBio is hiring for a Remote Neuromuscular Account Manager - New Orleans, LA in USA. Find more details about the job and how to apply at Built In. new orleans laaccount managerneuromuscularbridgebiobuilt https://www.biospace.com/press-releases/bridgebio-pharma-to-participate-in-the-j-p-morgan-healthcare-conference BridgeBio Pharma to Participate in the J.P. Morgan Healthcare Conference - BioSpace j p morganto participatein the https://investorplace.com/stock-quotes/bbio-stock-quote/ BRIDGEBIO PHARMA (BBIO) Latest News & Price | InvestorPlace Check out our BBIO stock analysis, current BBIO quote, charts, and historical prices for BRIDGEBIO PHARMA stock latest newsbridgebiopharmapriceinvestorplace https://investingnews.com/stocks/bbio/bridgebio-pharma/ BridgeBio Pharma Stock Price, News, Quote & History | INN Sep 11, 2025 - BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that... stock price newsquote historybridgebiopharmainn https://investingnews.com/bridgebio-to-present-long-term-efficacy-and-safety-data-from-the-attribute-cm-ole-trial-at-the-acc-annual-scientific-sessions/ BridgeBio to Present Long-Term Efficacy and Safety Data from the ATTRibute-CM OLE Trial at the ACC... Mar 23, 2026 - BridgeBio Pharma, Inc. (Nasdaq: BBIO) ("BridgeBio" or the "Company"), a biopharmaceutical company focused on developing medicines for genetic conditions,... https://www.nasdaq.com/market-activity/stocks/bbio/insider-activity BridgeBio Pharma, Inc. Common Stock (BBIO) Insider Activity | Nasdaq Find the latest information on BridgeBio Pharma, Inc. Common Stock (BBIO) insider activity and insider shares traded to make sound investments with Nasdaq.com. common stockbridgebiopharmaincinsider https://www.mdanderson.org/newsroom/archived-news/md-anderson-and-bridgebio-pharma-launch-navire-pharma-to-develop.h00-159149190.html ARCHIVED: MD Anderson and BridgeBio Pharma launch Navire Pharma to develop targeted therapy for... The University of Texas MD Anderson Cancer Center and BridgeBio Pharma today announced the launch of Navire Pharma, a biopharmaceutical company aimed at... https://www.flexjobs.com/remote-jobs/company/bridgebio_pharma BridgeBio Pharma - Remote Work From Home Jobs & Careers | FlexJobs Find remote work from home jobs and careers with BridgeBio Pharma. Get a better remote job search with FlexJobs today! remote work from homejobs careersbridgebiopharmaflexjobs https://investingnews.com/bridgebio-submits-nda-to-fda-for-bbp-418-for-individuals-living-with-lgmd2i-r9/ BridgeBio Submits NDA to FDA for BBP-418 for Individuals Living with LGMD2I/R9 | INN Mar 30, 2026 - - Comprehensive submission includes interim Phase 3 FORTIFY data demonstrating BBP-418's rapid, consistent treatment effect and favorable safety profile, with... https://www.benzinga.com/insights/options/25/02/44016728/10-health-care-stocks-whale-activity-in-todays-session 10 Health Care Stocks Whale Activity In Today's Session - AbbVie (NYSE:ABBV), BridgeBio Pharma... https://www.globenewswire.com/news-release/2023/08/27/2732246/0/en/BridgeBio-presents-detailed-positive-results-from-Phase-3-ATTRibute-CM-study-of-acoramidis-for-patients-with-transthyretin-amyloid-cardiomyopathy-ATTR-CM-at-European-Society-of-Car.html BridgeBio presents detailed positive results from Phase 3 positive resultsbridgebiopresentsdetailedphase https://www.benzinga.com/news/earnings/21/12/24781866/mid-morning-market-update-markets-open-higher-news-corp-to-buy-base-chemicals Mid-Morning Market Update: Markets Open Higher; News Corp To Buy Base Chemicals - BridgeBio Pharma... https://www.biospace.com/business/bridgebio-to-present-additional-analyses-from-the-phase-3-attribute-cm-trial-of-acoramidis-in-patients-with-transthyretin-amyloid-cardiomyopathy-attr-cm-at-the-esc-congress-2024-and-the-hfsa-annual-meeting-2024 BridgeBio to Present Additional Analyses from the Phase 3 ATTRibute-CM Trial of Acoramidis in... https://www.biospace.com/bridgebio-pharma-and-maze-therapeutics-establish-joint-venture-to-advance-precision-medicine-to-treat-cardiovascular-disease BridgeBio Pharma and Maze Therapeutics Establish Joint Venture to Advance Precision Medicine to... Dec 7, 2020 - BridgeBio Pharma, Inc. (Nasdaq: BBIO) and Maze Therapeutics today announced the establishment of a joint venture, Contour Therapeutics, focused on transforming... https://www.macrotrends.net/stocks/charts/BBIO/bridgebio-pharma/total-assets BridgeBio Pharma Total Assets 2018-2026 | BBIO | MacroTrends total assetsbridgebiopharmamacrotrends https://www.macrotrends.net/stocks/charts/BBIO/bridgebio-pharma/roe BridgeBio Pharma ROE 2018-2026 | BBIO | MacroTrends Current and historical return on equity (ROE) values for BridgeBio Pharma (BBIO) over the last 10 years. Return on equity can be defined as the amount of net... bridgebiopharmaroemacrotrends https://www.benzinga.com/24/11/42170458/crude-oil-down-2-chicago-fed-national-activity-index-falls-in-october Crude Oil Down 3%; Chicago Fed National Activity Index Falls In October - BridgeBio Pharma... https://www.macrotrends.net/stocks/charts/BBIO/bridgebio-pharma/price-book BridgeBio Pharma Price to Book Ratio 2018-2026 | BBIO | MacroTrends price to bookbridgebiopharmaratiomacrotrends https://www.benzinga.com/general/biotech/24/09/40819741/bridgebio-pharma-seeks-partner-to-develop-gene-therapy-for-inherited-condition BridgeBio Pharma Seeks Partner To Develop Gene Therapy For Inherited Condition - BridgeBio Pharma... Sep 11, 2024 - BridgeBio Pharma released Phase 1/2 trial results for BBP-631, its gene therapy for congenital adrenal hyperplasia. The study demonstrated increased cortisol... gene therapybridgebiopharmaseekspartner https://bbotx.com/ BridgeBio Oncology Therapeutics (BBOT) | Best-in-RAS Sep 11, 2025 - Redefining what’s possible in precision oncology to treat RAS-dependent cancers. Inhibiting Active RAS. Going beyond current approaches. best inbridgebiooncologytherapeuticsbbot https://www.macrotrends.net/stocks/charts/BBIO/bridgebio-pharma/current-ratio BridgeBio Pharma Current Ratio 2018-2025 | BBIO | MacroTrends Current and historical current ratio for BridgeBio Pharma (BBIO) from 2018 to 2025. Current ratio can be defined as a liquidity ratio that measures a company's... current ratiobridgebiopharmamacrotrends https://www.biospace.com/invitae-partners-with-bridgebio-pharma-to-harness-genetic-insights-for-the-discovery-of-rare-disease-therapeutics Invitae Partners with BridgeBio Pharma to Harness Genetic Insights for the Discovery of Rare... Jan 30, 2024 - Invitae (NYSE: NVTA), a leading medical genetics company, today announced a partnership with BridgeBio Pharma, Inc. (Nasdaq: BBIO), a commercial-stage... https://www.nasdaq.com/market-activity/stocks/bbio/option-chain BridgeBio Pharma, Inc. Common Stock (BBIO) Option Chain | Nasdaq View the most recent data and latest information on option chains for BridgeBio Pharma, Inc. Common Stock (BBIO) at Nasdaq.com. common stockoption chainbridgebiopharmainc https://www.biospace.com/press-releases/bridgebio-to-host-limb-girdle-muscular-dystrophy-type-2i-r9-investor-webinar-on-friday-july-11th-at-8-00-am-et BridgeBio to Host Limb-girdle Muscular Dystrophy Type 2I/R9 Investor Webinar on Friday, July 11th... https://www.biospace.com/press-releases/bridgebio-pharma-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-april-11-2025 BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - April 11, 2025 -... https://www.biospace.com/bridgebio-pharma-reports-fourth-quarter-and-full-year-2022-financial-results-and-business-update BridgeBio Pharma Reports Fourth Quarter and Full Year 2022 Financial Results and Business Update -... Feb 23, 2023 - BridgeBio Pharma, Inc. today reported its financial results for the fourth quarter and full year ended December 31, 2022 and provided an update on the... https://www.fiercebiotech.com/biotech/bridgebio-stuffs-125b-its-coffers-fund-showdown-pfizer BridgeBio taps investors for $1.25B to fund showdown with Pfizer Jan 18, 2024 - Facing a deep-pocketed rival, the biotech has struck deals to support an anticipated launch and a schedule of phase 3 readouts for other assets. bridgebiotapsinvestors https://builtin.com/job/neuromuscular-account-manager-san-francisco-ca/8992828 Neuromuscular Account Manager - San Francisco, CA - BridgeBio | Built In BridgeBio is hiring for a Remote Neuromuscular Account Manager - San Francisco, CA in USA. Find more details about the job and how to apply at Built In. san francisco caaccount managerneuromuscularbridgebiobuilt https://www.fiercebiotech.com/biotech/bridgebio-heart-disease-drug-vindicated-phase-3-victory-plots-fda-submission-23 BridgeBio heart disease med vindicated with phase 3 victory Jul 17, 2023 - BridgeBio was hesitant about committing to a potential partnership for its heart disease drug, though investors appear to be expecting one. heart diseasebridgebiomedvindicatedphase https://www.globenewswire.com/news-release/2020/10/21/2111765/0/en/BridgeBio-Pharma-Inc-and-the-University-of-Colorado-Anschutz-Medical-Campus-Collaborate-to-Advance-Medicines-for-Genetically-Driven-Diseases.html BridgeBio Pharma, Inc. and the University of Colorado PALO ALTO, Calif. and DENVER, Oct. 21, 2020 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) and the University of Colorado Anschutz Medical... and theuniversity ofbridgebiopharmainc https://www.biospace.com/press-releases/bridgebio-to-host-first-quarter-2025-financial-results-conference-call-on-tuesday-april-29-2025-at-4-30-pm-et BridgeBio to Host First Quarter 2025 Financial Results Conference Call on Tuesday, April 29, 2025... https://builtin.com/job/neuromuscular-account-manager-boston-ma/8992820 Neuromuscular Account Manager - Boston, MA - BridgeBio | Built In BridgeBio is hiring for a Remote Neuromuscular Account Manager - Boston, MA in USA. Find more details about the job and how to apply at Built In. account managerneuromuscularbostonbridgebiobuilt https://www.macrotrends.net/stocks/charts/BBIO/bridgebio-pharma/return-on-tangible-equity BridgeBio Pharma Return on Tangible Equity 2018-2026 | BBIO | MacroTrends Current and historical return on tangible equity values for BridgeBio Pharma (BBIO) over the last 10 years. Return on tangible equity can be defined as the... bridgebiopharmareturntangibleequity https://www.macrotrends.net/stocks/charts/BBIO/bridgebio-pharma/revenue BridgeBio Pharma Revenue 2018-2025 | BBIO | MacroTrends BridgeBio Pharma annual/quarterly revenue history and growth rate from 2018 to 2025. Revenue can be defined as the amount of money a company receives from its... bridgebiopharmarevenuemacrotrends https://www.macrotrends.net/stocks/charts/BBIO/bridgebio-pharma/debt-equity-ratio BridgeBio Pharma Debt to Equity Ratio 2018-2026 | BBIO | MacroTrends Current and historical debt to equity ratio values for BridgeBio Pharma (BBIO) over the last 10 years. The debt/equity ratio can be defined as a measure of a... debt to equity ratiobridgebiopharmamacrotrends https://www.benzinga.com/general/biotech/22/05/27163467/bridgebio-inks-licensing-pact-with-bristol-myers-for-shp2-inhibitor-in-oncology BridgeBio Inks Licensing Pact With Bristol Myers For SHP2 Inhibitor In Oncology - BridgeBio Pharma... https://www.macrotrends.net/stocks/charts/BBIO/bridgebio-pharma/roa BridgeBio Pharma ROA 2018-2026 | BBIO | MacroTrends Current and historical return on assets (ROA) values for BridgeBio Pharma (BBIO) over the last 10 years. Return on assets can be defined as an indicator of how... bridgebiopharmaroamacrotrends https://www.macrotrends.net/stocks/charts/BBIO/bridgebio-pharma/gross-margin BridgeBio Pharma Gross Margin 2018-2026 | BBIO | MacroTrends Current and historical gross margin for BridgeBio Pharma (BBIO) over the last 10 years. The current gross profit margin for BridgeBio Pharma as of March 31,... gross marginbridgebiopharmamacrotrends https://www.fiercebiotech.com/biotech/kkr-viking-global-lead-299m-round-for-bridgebio KKR, Viking Global lead $299M round for BridgeBio | Fierce Biotech Jan 23, 2019 - BridgeBio Pharma has bagged a whopping $299.2 million kkrvikinggloballeadround https://builtin.com/job/neuromuscular-account-manager-upstate-ny/8992834 Neuromuscular Account Manager - Upstate NY - BridgeBio | Built In BridgeBio is hiring for a Remote Neuromuscular Account Manager - Upstate NY in USA. Find more details about the job and how to apply at Built In. account managerupstate nyneuromuscularbridgebiobuilt https://builtin.com/company/bridgebio BridgeBio Careers, Perks + Culture | Built In Learn more about BridgeBio. Find jobs, explore benefits, and research company culture at Built In. bridgebiocareersperksculturebuilt https://www.insidermonkey.com/blog/bridgebio-pharma-raises-300m-through-partial-european-royalty-monetization-for-beyonttra-1563615/ BridgeBio Pharma Raises $300M Through Partial European Royalty Monetization for BEYONTTRA - Insider... BridgeBio Pharma Inc. (NASDAQ:BBIO) is one of the best high short interest stocks with huge upside potential. https://www.biospace.com/bridgebio-spins-out-oncology-company-with-200m-in-financing BridgeBio Spins Out Oncology Company with $200M in Financing - BioSpace Jul 23, 2024 - The new company, BridgeBio Oncology Therapeutics, is looking to advance two KRAS inhibitors and a blocker of the interaction between the RAS and PI3K pathways. bridgebiospinsoncologycompanyfinancing https://www.fiercebiotech.com/biotech/maze-allies-bridgebio-and-alloy-to-create-2-biotechs Maze allies with BridgeBio and Alloy to create 2 biotechs | Fierce Biotech Dec 7, 2020 - Maze Therapeutics has https://builtin.com/job/neuromuscular-account-manager-minneapolis-mn/8992781 Neuromuscular Account Manager - Minneapolis, MN - BridgeBio | Built In BridgeBio is hiring for a Remote Neuromuscular Account Manager - Minneapolis, MN in USA. Find more details about the job and how to apply at Built In. account managerminneapolis mnneuromuscularbridgebiobuilt https://www.macrotrends.net/stocks/charts/BBIO/bridgebio-pharma/quick-ratio BridgeBio Pharma Quick Ratio 2018-2026 | BBIO | MacroTrends Historical quick ratio values for BridgeBio Pharma (BBIO) over the last 10 years. quick ratiobridgebiopharmamacrotrends https://www.biospace.com/bridgebio-partners-with-leading-cardiovascular-data-science-lab-cards-lab-to-improve-transthyretin-amyloid-cardiomyopathy-attr-cm-diagnosis-in-diverse-patient-populations-with-multimodal-artificial-intelligence BridgeBio Partners with Leading Cardiovascular Data Science Lab (CarDS Lab) to Improve... data science labbridgebiopartnersleadingcardiovascular https://builtin.com/job/neuromuscular-account-manager-san-diego-ca/8992791 Neuromuscular Account Manager - San Diego, CA - BridgeBio | Built In BridgeBio is hiring for a Remote Neuromuscular Account Manager - San Diego, CA in USA. Find more details about the job and how to apply at Built In. san diego caaccount managerneuromuscularbridgebiobuilt https://www.benzinga.com/general/biotech/23/11/35668870/why-is-biomarin-bridgebio-pharma-rival-lumos-pharma-stock-trading-higher-today Why Is Biomarin & BridgeBio Pharma Rival Lumos Pharma Stock Trading Higher Today? - Benzinga Nov 8, 2023 - Lumos Pharma Inc (NASDAQ: LUMO) announced that topline results from its Phase 2 OraGrowtH210 dose-finding trial and its Phase 2 OraGrowtH212... https://www.home.saxo/nl-be/markets/stocks/bbio-xnas BridgeBio Pharma Inc. aandeel | Saxo Bank BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic... bridgebiopharmaincaandeelsaxo https://www.macrotrends.net/stocks/charts/BBIO/bridgebio-pharma/profit-margins BridgeBio Pharma Profit Margin 2018-2026 | BBIO | MacroTrends Current and historical gross margin, operating margin and net profit margin for BridgeBio Pharma (BBIO) over the last 10 years. Profit margin can be defined as... profit marginbridgebiopharmamacrotrends https://www.macrotrends.net/stocks/charts/BBIO/bridgebio-pharma/stock-price-history BridgeBio Pharma - 7 Year Stock Price History | BBIO | MacroTrends Historical daily share price chart and data for BridgeBio Pharma since 2019 adjusted for splits and dividends. The latest closing stock price for BridgeBio... stock pricebridgebiopharmayearhistory https://builtin.com/job/neuromuscular-account-manager-connecticut/8992823 Neuromuscular Account Manager - Connecticut - BridgeBio | Built In BridgeBio is hiring for a Remote Neuromuscular Account Manager - Connecticut in USA. Find more details about the job and how to apply at Built In. account managerneuromuscularconnecticutbridgebiobuilt https://reurl.cc/Eg3xqm BridgeBio Oncology Takes Unexpected SPAC Track to Public Markets in $450M Deal In a move straight out of 2021, BridgeBio Oncology is taking the SPAC route to the public markets in... https://www.biospace.com/bridgebio-pharma-to-present-additional-analyses-from-the-phase-3-attribute-cm-study-of-acoramidis-in-patients-with-transthyretin-amyloid-cardiomyopathy-attr-cm-at-the-2024-isa-meeting BridgeBio Pharma to Present Additional Analyses from the Phase 3 ATTRibute-CM Study of Acoramidis... May 27, 2024 - BridgeBio Pharma, Inc. announced that 12 oral and moderated poster presentations will be shared at the 2024 International Symposium on Amyloidosis, taking... https://www.entrepreneur.com/finance/bridgebios-volatile-week-puts-biotech-stocks-under-a/447632 BridgeBio's Volatile Week Puts Biotech Stocks Under a Microscope Aug 29, 2025 - BridgeBio's recent volatility is a perfect example of how good news often turns into bad news for biopharmaceutical companies. biotech stocksbridgebiovolatileweekputs https://www.nasdaq.com/market-activity/stocks/bbio/press-releases BridgeBio Pharma, Inc. Common Stock (BBIO) Press Releases | Nasdaq Get the latest insights on BridgeBio Pharma, Inc. Common Stock (BBIO) with press releases and corporate news to help you in your trading and investing... common stockpress releasesbridgebiopharmainc https://www.flexjobs.com/gjw/bridgebio-pharma/medical-director-drug-safety/publicjobs?id=3b63cd37-d0c7-4c1f-9c5c-9c8c1b0620f2 Medical Director, Drug Safety Job at BridgeBio Pharma Apply for the Medical Director, Drug Safety job at BridgeBio Pharma. View the job description, responsibilities and qualifications. medical directordrug safetyjobbridgebiopharma